Sunday, November 23, 2014
 
PREDIMED Study Group Minimize

             

 The multidisciplinary team of the PREDIMED study assembles outstanding research groups involved in nutrition and cardiovascular risk in Spain. Partners are 16 groups distributed in 7 autonomous communities in Spain, which are formed by university researchers, hospital clinicians, primary care physicians, nutritionists and epidemiologists working in various public institutions. The team takes advantage of modern communication technologies and performs as a research network, thus allowing complementariness of aims, deeper commitment into research proposals, and optimization of resources. The setting up of the PREDIMED team has meant the union for a common goal of a critical mass of Spanish investigators able to compete in a project of worldwide importance with those of the rest of Europe or the US. Within this context, a coordinated project was designed to study the effects of the Mediterranean diet on the primary prevention of cardiovascular diseases, the PREDIMED study. The project started in October 2003 and up to date has recruited nearly 7000 asymptomatic participants at high cardiovascular risk, who will be followed for a an average period of 5 years. Its main outcome is incident cardiovascular disease, secondary outcomes are all cause mortality and incidence of other chronic diseases, and tertiary outcomes are changes in risk biomarkers.

            

 PREDIMED is the acronym of a long-term nutritional intervention study aimed to assess the efficacy of the Mediterranean diet in the primary prevention of cardiovascular diseases, the complete title of which is “Effects of the Mediterranean diet on the primary prevention of cardiovascular diseases”. It is a large randomized clinical trial of dietary intervention in persons at high risk of cardiovascular disease. The main objective is to evaluate whether the Mediterranean diet supplemented with extra-virgin olive oil or tree nuts prevents cardiovascular diseases (cardiovascular death, myocardial infarction and/or stroke), by comparison with a low-fat diet. As secondary variables, the preventive efficacy of the Mediterranean diet will also be assessed on all-cause mortality and incidence of heart failure, diabetes, cancer, dementia and other neurodegenerative diseases. The trial is registered in the London-based Current Controlled Trials register with ISRCTN number 35739639 (http://www.controlled-trials.com/ISRCTN35739639).

             PREDIMED was launched in 2003 thanks to a grant from Instituto de Salud Carlos III (ISCIII) of the Spanish Health Ministry, the Thematic Network of Cooperative Investigation G03/140. Presently the study is supported by two additional ISCIII initiatives, CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn) and Network RD 06/0045. PREDIMED could not have started or be ongoing without the generous donation of supplemental foods: extra-virgin olive oil (Hojiblanca S.A. and Patrimonio Comunal Olivarero, Spain), walnuts (California Walnut Commission, Sacramento, California, USA), almonds (Borges S.A., Reus, Spain) and hazelnuts (Morella Nuts, Reus, Spain).

             The team of the PREDIMED study is coordinated from Hospital Clínic, University of Barcelona, Spain by Dr. Ramón Estruch, who also leads the groups included in CIBERobn. The leader of Network RD 06/0045, which provides funding for the remaining PREDIMED partners, is Dr. Miguel Ángel Martínez-González, University of Navarra, Spain.

                                            


Copyright 2009 by Predimed onmedic                              Privacy Statement  Terms Of Use